m6A-centered Drug Response Information
General Information of the Drug (ID: M6ADRUG0054)
| Name |
PLX4032
|
||||
|---|---|---|---|---|---|
| Synonyms |
PLX4032; RG7204; RO5185426; Zelboraf (TN); Vemurafenib (BRAF inhibitor)
Click to Show/Hide
|
||||
| Status | Approved | [1] | |||
| Structure |
 |
||||
| Formula |
C23H18ClF2N3O3S
|
||||
| InChI |
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)
|
||||
| InChIKey |
GPXBXXGIAQBQNI-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
| DrugBank ID | |||||
Full List of m6A Targets Related to This Drug
Epidermal growth factor receptor (EGFR)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene | [2] | |||
| Response Summary | METTL3 increased the m6A modification of Epidermal growth factor receptor (EGFR) mRNA in A375R cells, which promoted its translation efficiency. Inhibiting METTL3 function to restore PLX4032 sensitivity in patients with melanoma. | |||
| Responsed Disease | Melanoma | ICD-11: 2C30 | ||
| Target Regulator | Methyltransferase-like 3 (METTL3) | WRITER | ||
| Target Regulation | Up regulation | |||
| Pathway Response | EGFR tyrosine kinase inhibitor resistance | hsa01521 | ||
| Cell Process | Cell apoptosis | |||
| In-vitro Model | A375-R | Amelanotic melanoma | Homo sapiens | CVCL_6234 |
References